Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma

Atractylodes lancea (Thunb) DC. and its bioactive compound atractylodin (ATD), have been shown to exert promising anticancer activity against cholangiocarcinoma (CCA) both in vitro and in vivo. However, the clinical development of ATD could be hindered due to hydrophobicity and poor pharmacokinetic properties, and thus, the requirement of high dose administration and the risk of toxicity. In the present study, ATD-loaded in PLGA nanoparticles (ATD-PLGA) and that coated with chitosan (ATD-PLGA-CS) were developed using nanoprecipitation and single emulsification methods, respectively. The optimized ATD-PLGA formulation provided superior physical and pharmaceutical properties over ATD-PLGA-CS. The antiproliferative activity of ATD-PLGA against the two CCA cell lines, HuCCT1 and CL6, and the normal cell line (OUMS-36T-1F) was evaluated using MTT assay. Results showed that normal epithelial cell was less sensitive to ATD-PLGA compared to both CCA cell lines. In mice, the radiolabelled Tc-99m-ATD-PLGA showed superior pharmacokinetic profile over free Tc-99m-ATD, as evidenced by a 2.7-fold increase of area under plasma concentration-time curve (AUC(0-infinity)), maximum plasma concentration (C-max), time to C-max (t(max)), and mean residence time (MRT). Higher accumulation of Tc-99m-ATD-PLGA was observed in vital organs/tissues such as blood, liver, heart, and kidney, compared with free Tc-99m-ATD-PLGA. Altogether, the results suggest that PLGA NPs could be a suitable drug delivery carrier for ATD in CCA.

Automated summary

The study demonstrated the promising anticancer activity of ATD-loaded PLGA nanoparticles against cholangiocarcinoma cells and the superior pharmacokinetic profile of radiolabelled Tc-99m-ATD-PLGA in mice, suggesting PLGA NPs as a suitable drug delivery carrier for CCA treatment.